News Alert

Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals

Pfizer company name on a building
Drug manufacturer Pfizer stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz.

Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.

Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer

Read More »

ASAP 340B Hires Executive Director and Publishes FAQ in Response to Questions and Criticism

ASAP 340B partnership wordmark
ASAP 340B this week announced it hired an executive director and published an FAQ that responds to questions and criticism.

ASAP 340B, the nonprofit group that the drug industry and health centers formed to help advance their joint plan to remake the 340B program, has hired an executive director and published an FAQ that responds to questions and criticism. “There

Read More »

AIDS Healthcare Foundation Protests Against PhRMA/NACHC Alliance During 340B Coalition Conference

Protesters carry placards in support of the 340B drug pricing program and AHF
AIDS Healthcare Foundation held a protest march Tuesday at the 340B Coalition winter conference in California against the PhRMA/NACHC alliance to change the 340B program.

AIDS Healthcare Foundation held two demonstrations Tuesday—one outdoors and loud, the other indoors and silent—at the 340B Coalition winter conference in California to protest against the new drug industry/community health center alliance to change the 340B program.

“Let’s be clear.

Read More »

News Alert

AbbVie Puts Squeeze on 340B Pricing for Hospitals Akin to J&J and Amgen’s Recent Moves

AbbVie facility gate
AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals, along the lines of Amgen and Johnson & Johnson's recent moves.

Drug manufacturer AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals.

AbbVie has not yet responded to a request for comment about the changes. Non-hospital covered entities continue to be exempt from AbbVie’s pricing restrictions.

Drug manufacturers

Read More »

RWC-340B Opposes and Hemophilia Alliance Questions PhRMA and NACHC’s Push to Remake 340B

RWC-340B Hemophilia Alliance wordmarks
RWC-340B rejected and Hemophilia Alliance criticized PhRMA and NACHC's joint plan to restructure the 340B program.

Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net providers.”

Hemophilia

Read More »

Confidential Document Fleshes Out ASAP 340B’s Reform Objectives

Excerpt from a confidential PhRMA principles document
PhRMA has written an eight-page document that elaborates on its principles for 340B program reform.

A confidential document composed by Pharmaceutical Research and Manufacturers of America in connection with its 340B program reform initiative with the National Association of Community Health Centers fleshes out a “coalition” vision of the 10-point reform plan that the two

Read More »

340B Hospitals Say Pharma’s Contract Pharmacy Policies Are Costing Them “Billions of Dollars”

340B Hospital savings by drug company bar chart
340B Health says, "For just the first five of the 21 drug companies for which there is a full year of data post-restrictions, the 340B savings for hospitals decreased by an estimated $1.1 billion from 2020 to 2021."

Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in a new

Read More »

PhRMA Discusses Joint 340B Reform Deal with Health Centers in Interview; Hospital Groups Denounce Plan

Nicole Longo headshot
“There is no way for 340B to be fixed without everybody coming to the table,” PhRMA spokesperson Nicole Longo said in an interview with 340B Report.

The fallout continues from drug makers and health centers’ decision to work together to change the 340B program, with the drug industry giving its first interview about the deal to 340B Report on Friday and several hospital groups jointly blasting

Read More »

News Alert

Amgen Expands 340B Contract Pharmacy Limits

Amgen wordmark on building
Amgen today announced a major expansion of its conditions on 340B pricing when hospitals use contract pharmacies.

Biopharmaceutical manufacturer Amgen this afternoon significantly expanded its conditions on 340B pricing when hospitals use contract pharmacies.

Johnson & Johnson announced a similar expansion of its 340B contract pharmacy limits last month. Hospital groups slammed J&J’s new restrictions.

Amgen’s

Read More »

News Alert

Some Provider Groups Slam NACHC and PhRMA’s 340B Plan, Others Say They’re Studying it

NACHC P&I 2023 speaker at podium
Lt. Cmdr. Emeka Egwim (left), Director of HRSA's Office of Pharmacy Affairs, spoke this morning on 340B Day at NACHC's annual Policy & Issues Forum in Washington, D.C.

A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program. Other 340B

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live